RNC Minerals Produces 13,497 oz of Gold in October 2018

RNC Minerals Corporation (“RNC”) (TSX:RNX) is pleased to report production from the Beta Hunt Mine of 13,497 mined gold ounces for the month of October 2018 at an average grade of 9.06 g/t. Year-to-date October 31, 2018 mined gold ounces was 71,957, an increase of 60% versus the prior year period, including 25,355 ounces thus far from the Father’s Day Vein and a total of 30,145 ounces of high grade coarse gold from all areas. The production table below (Table 1) breaks out production of high grade coarse gold and total gold production. Mining of high grade coarse gold has resumed in the Father’s Day Vein discovery area.

Mark Selby, President and CEO of RNC, commented, “October was another excellent production month for the Company as we recovered an additional 8,506 ounces of high grade coarse gold. RNC is in a solid cash position with a cash and cash equivalents balance (including specimens held for sale valued at gold content) as of November 9, 2018 of $ 18.8 million – sufficient to fund the company’s planned upcoming activities. Drilling along strike from the Father’s Day Vein discovery area in the A Zone is underway and a second drill has arrived at site to begin resource definition drilling and target the sediment layer in the much larger Western Flanks structure. We expect our exploration program to add additional gold ounces going forward as we define and explore sediment structures throughout the Beta Hunt mine.”

Table 1: Beta Hunt Mine Year-to-Date October 31, 2018 Production Results

Beta Hunt Gold Operation1 Q1 2018 Q2 2018 Q3 2018 Oct 2018 YTD 2018
Gold tonnes mined (000s) 169 132 146 46 493
Gold mined grade (g/t Au)3,4 2.54 3.14 6.67 9.06 4.54
Gold mined – coarse gold / specimens (ounces) 381 1,841 19,417 8,506 30,145
Gold mined (ounces) 13,399 11,479 11,943 4,991 41,812
Total gold mined (ounces)2,3,4 13,780 13,320 31,360 13,497 71,957
Gold tonnes milled (000s) 110 112 199 33 454
Gold mill grade (g/t Au) 2.36 3.28 3.93 14.74 4.17
Gold Recovery (%) 90% 91% 95% 95% 93%
Gold milled (ounces) 8,372 11,844 25,1285 15,497 60,841
Gold sales (ounces)1 7,978 11,511 23,805 15,233 58,527

 

Note that October 2018 sales and production numbers are preliminary estimates. Final grades and ounces can only be determined once mined material has been processed.

1. Note: numbers may not add due to rounding.
2. The difference in gold sales ounces and gold mined ounces is due to timing differences in receipt of gold sales depending on completion date of tolling campaigns.
3. Final grades are determined once mined material has been processed.
4. As of October 31, 2018, 84.1 kt of gold mineralization remained on the ROM pad for tolling, as compared to 70.5 kt of gold mineralization as of September 30, 2018.
5. Milled ounces is corrected from previously reported number of 33,725 ounces.

Technical Disclosure

The disclosure of scientific and technical information contained in this news release has been approved by Kevin Small, Chief Operating Officer, Salt Lake Mining and Vice President, Project Development of RNC, a Qualified Person under NI 43-101.

Third Quarter 2108 Conference Call / Webcast
RNC will be hosting a conference call and webcast tomorrow (November 13) beginning at 10:00 a.m. (Eastern time).

Live Conference Call and Webcast Access Information:
North American callers please dial: 1-888-231-8191
Local and international callers please dial: 647-427-7450
A live webcast of the call will be available through Cision’s website at: www.newswire.ca/en/webcast/index.cgi

A recording of the conference call will be available for replay for a one week period beginning at approximately 1:00 p.m. (Eastern Time) on November 13, 2018, and can be accessed as follows:
North American callers please dial: 1-855-859-2056; Pass Code: 7283426
Local and international callers please dial: 416-849-0833; Pass Code: 7283426

About RNC Minerals
RNC has a 100% interest in the producing Beta Hunt gold mine located in Western Australia where a significant high grade gold discovery – “Father’s Day Vein” – was recently made. Beta Hunt gold resource potential is underpinned by multiple gold shears with gold intersections across a 4 km strike length which remain open in multiple directions adjacent to an existing 5 km ramp network. RNC also has a 28% interest in a nickel joint venture that owns the Dumont Nickel-Cobalt Project located in the Abitibi region of Quebec which contains the second largest nickel reserve and eighth largest cobalt reserve in the world. RNC owns a 35% interest in Orford Mining Corporation, a mineral explorer focused on highly prospective and underexplored areas of Northern Quebec and the U.S. Carolina Gold Belt. RNC has a strong management team and Board with over 100 years of mining experience. RNC’s common shares trade on the TSX under the symbol RNX. RNC shares also trade on the OTCQX market under the symbol RNKLF.

Cautionary Statement Concerning Forward-Looking Statements

This news release contains “forward-looking information” including without limitation statements relating to the liquidity and capital resources of RNC, production guidance and the potential of the Beta Hunt Mine.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of RNC to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that could affect the outcome include, among others: future prices and the supply of metals; the results of drilling; inability to raise the money necessary to incur the expenditures required to retain and advance the properties; environmental liabilities (known and unknown); general business, economic, competitive, political and social uncertainties; results of exploration programs, accidents, labour disputes and other risks of the mining industry; political instability, terrorism, insurrection or war; or delays in obtaining governmental approvals, projected cash costs, failure to obtain regulatory or shareholder approvals. For a more detailed discussion of such risks and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, refer to RNC’s filings with Canadian securities regulators available on SEDAR at www.sedar.com.

Although RNC has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Forward-looking statements contained herein are made as of the date of this news release and RNC disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.

The post RNC Minerals Produces 13,497 oz of Gold in October 2018 appeared first on Investing News Network.

Investing News Network

Will Crude Oil Price Find Support Near $60?

Article posted at The Market Oracle http://www.marketoracle.co.uk/Article63513.html
The Market Oracle – Financial Markets Analysis and Forecasts – CLICK TO READ ARTICLE

Gerardo Del Real: This is the “Buy Low” Part of “Buy Low, Sell High”

This year has not been as positive as some resource investors initially hoped, but many experts believe that just means opportunity is around the corner.

Gerardo Del Real of the Outsider Club thinks just that, and speaking to the Investing News Network at the recent New Orleans Investment Conference he explained why.

“[In] this space it’s a tough market right now for a lot of the juniors. This is exactly the time you should be identifying those quality management teams and writing cheques for them and purchasing the stock. This the ‘buy low’ part of ‘buy low and sell high,’” he explained.

Lithium in 2018

Your free report includes:

  • Expert commentary
  • Stocks to buy
  • Market forecasts

Give me my free report!

In terms of where he sees opportunity, Del Real pointed to uranium as a market where there are gains to be made. “This is my first year saying that I believe we’re at a bottom,” he joked, noting that he’s encouraged by supply cuts and the fact that utilities will have to come back into the market in 2019.

He added, “the good news is for speculators in the space there’s not a lot of uranium companies left.”

Del Real also believes there is still room to make money in the lithium arena, describing it as “way oversold” from an equities perspective. “The bottom line is there’s not a lot of great lithium assets in the world. So find juniors that have strategic locations, plenty of water, good management teams,” he said.

Watch the interview above for more insight from Del Real, including several stocks he likes in the uranium and lithium spaces. You can also click here to see the full New Orleans Investment Conference playlist on YouTube.

Don’t forget to follow us @INN_Resource for real-time updates!

Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: Advantage Lithium, Azarga Uranium and Energy Fuels are clients of the Investing News Network. This article is not paid-for content. 

The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

The post Gerardo Del Real: This is the “Buy Low” Part of “Buy Low, Sell High” appeared first on Investing News Network.

Investing News Network

Fr. 1514 $2 1963A Legal Tender Note PMG 66EPQ Gem Uncirculated Red Seal

$43.00
End Date: Monday Dec-10-2018 12:39:27 PST
Buy It Now for only: $43.00
Buy It Now | Add to watch list

View full post on

2009 Graded Silver Eagle PCGS MS70

$25.25 (4 Bids)
End Date: Tuesday Nov-13-2018 21:40:12 PST
Bid now | Add to watch list

View full post on

Olympus Tough TG-5 Camera Stuck or Dead Pixels, Rubbish Video Auto Focus

Article posted at The Market Oracle http://www.marketoracle.co.uk/Article63504.html
The Market Oracle – Financial Markets Analysis and Forecasts – CLICK TO READ ARTICLE

Joe Lowry: Debunking the Lithium “Oversupply Myth”

Many market participants would agree that lithium oversupply fears have been a main factor impacting the space this year. In fact, and despite the positive demand narrative, share prices have not performed as expected, with many juniors taking a hit after Morgan Stanley (NYSE:MS) released a report predicting lithium prices would fall by 2021.

At this year’s Cathodes event in Newport Beach, the Investing News Network sat down with lithium expert Joe Lowry, president of Global Lithium, to discuss the lithium “oversupply myth,” what’s his take on demand and what to expect in the lithium sector next year.

Speaking about the reports published earlier this year about lithium, Lowry said the “tsunami of supply” predicted by some has not happened yet, and explained where he thinks the confusion is coming from.

He also mentioned prices as another of the big challenges in the lithium space this year.

“One small parameter [of lithium prices] is what goes on in China in the spot market,” he said, adding that this year, “the investment community fixated on Chinese lithium prices going down.”

According to Lowry, the positive surprises in 2018 have been on the demand side, as demand is still robust in Asia.

The expert also discusses where he thinks supply will come from in the next 3 to 5 years, and shares his thoughts on hard rock and brine projects.

“Existing players will continue to need expansions, developments or will need to acquire juniors or interest in juniors,” he said.

Lowry also talks about new battery technology, financing and gives his best suggestion for investors looking to jump into the lithium space.

Listen to the interview above for more insight from Lowry, who also talks about what’s ahead for the lithium podcast in season 2. You can also click here to listen to our full Cathodes interviews playlist on YouTube.

Don’t forget to follow us @INN_Resource for real-time updates!

Securities Disclosure: I, Priscila Barrera, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in contributed article. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

The post Joe Lowry: Debunking the Lithium “Oversupply Myth” appeared first on Investing News Network.

Investing News Network

$20 1934 San Francisco LGS Note. Light Green Seal. PMG 66 EPQ. Top Pop. 1/0

$5,000.00
End Date: Tuesday Dec-11-2018 18:32:04 PST
Buy It Now for only: $5,000.00
Buy It Now | Add to watch list

View full post on

2013 1oz American Silver Eagle PCGS MS 70 First Strike Mercanti Autograph Spots

$0.01 (1 Bid)
End Date: Saturday Nov-17-2018 16:49:34 PST
Bid now | Add to watch list

View full post on

Cyclical Commodities Continue to Weaken, Gold Moves in Relation

Article posted at The Market Oracle http://www.marketoracle.co.uk/Article63505.html
The Market Oracle – Financial Markets Analysis and Forecasts – CLICK TO READ ARTICLE

Bill Murphy: Don’t Give Up — Gold is Headed for a Big Move Higher

Bill Murphy, chairman of the Gold Anti-trust Action Committee (GATA), believes an explosive move in gold and silver prices is in the cards — but not before manipulation comes to an end.

“This past year and years have been so frustrating because other assets have soared … the stock market, the cryptocurrencies, art, real estate. And gold and silver have just been in the weeds,” he said on the sidelines of the recent New Orleans Investment Conference.

“From our standpoint … it’s all because of the gold cartel,” Murphy continued. “The government’s going to use all this quantitative easing, they’re going to budget deficits, debt’s going to go like crazy, interest rates are going to go to zero — and gold and silver will go back to where they are now?”

When asked what investors should do in the face of these circumstances, Murphy encouraged them not to give up. “I write a commentary every day, and go out and try to keep people in the game,” he said. “It’s no fun writing about what the gold cartel is doing to keep the prices in the dumpster. A lot of people have left and they’ve given up, it’s just human nature.”

However, he emphasized, “this has created a big-picture sentiment that’s going to lead to one of the big moves of all time.” And, Murphy added, “when it goes this time I don’t think we’re going to have the gradual moves like we saw at the early part of the decade — it’s going to be explosive.”

Listen to the interview above for insight from Murphy on gold market manipulation. You can also click here to see the full New Orleans Investment Conference playlist on YouTube.

Don’t forget to follow us @INN_Resource for real-time updates!

Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

Is it a good time to buy gold stocks?

Learn to profit from gold’s low price this year!

The post Bill Murphy: Don’t Give Up — Gold is Headed for a Big Move Higher appeared first on Investing News Network.

Investing News Network

$20 1934 Philadelphia Mule FRN. Fr. 2054-Cdgsm. PMG 66 EPQ. Scarce Note

$299.00
End Date: Wednesday Dec-12-2018 17:59:34 PST
Buy It Now for only: $299.00
Buy It Now | Add to watch list

View full post on

2018-P Australia Silver Kookaburra (1 oz) $1 – PCGS MS70 – First Strike

$40.00
End Date: Wednesday Dec-12-2018 16:09:02 PST
Buy It Now for only: $40.00
Buy It Now | Add to watch list

View full post on

What Is the Difference Between Democrats and Republicans?

Article posted at The Market Oracle http://www.marketoracle.co.uk/Article63506.html
The Market Oracle – Financial Markets Analysis and Forecasts – CLICK TO READ ARTICLE

Better Together: Strategic Partnerships in the Cannabis Market

Evolving every day, strategic partnerships in the cannabis market are helping to shape the industry.

The spreading legalization of both medical and recreational cannabis here in North America and abroad is allowing the cannabis industry to advance both in terms of clinical research and technological innovation, from cultivation practises to cannabinoid delivery systems. At the same time the growing global health and wellness trend is opening up new market segments for downstream cannabis products.

Within this shifting paradigm, licensed producers are partnering with biotechnology, pharmaceutical, and health and wellness companies as well as other cannabis-based companies to develop new cannabis delivery technologies and beneficial cannabis consumer products. For example, Aurora Cannabis (NYSE:ACB,TSX:ACB) recently partnered with Evio Beauty Group to collaboratively develop a line of hempseed oil product formulations and CBD-infused cosmetics. The partnership will give both companies increased brand recognition and cross-selling opportunities.

This INNspired Article is brought to you by:

Canntab Therapeutics (CSE:PILL) is bringing pharmaceutical expertise to the cannabis market through the development of its patent-pending Canntab Extended Release (XR) Tablets™.Send me an Investor Kit

Licensed producer Tilray (NASDAQ:TLRY) has partnered with Sandoz Canada, a subsidiary of one of the biggest pharmaceutical companies, Novartis (NYSE:NVS) to produce co-branded cannabis-based medical products such as gel caps and sprays for wholesale distribution to Canadian hospitals and pharmacies. Downstream cannabis extraction company MediPharm Labs (TSXV:LABS) recently entered into a strategic partnership with licensed producer Emerald Health Therapeutics (TSXV:EMH,OTCQX:EMHTF) in which Emerald will provide MediPharm with dried cannabis to create premium quality pharmaceutical grade cannabis oil.

High-margin cannabis consumer product market

Today’s cannabis market is moving well beyond big leafy buds as consumers are increasingly interested in alternative consumption methods to smoking dried flower. Cannabis legalization in Canada and many jurisdictions in the United States has led to growth in not only the medical marijuana and recreational adult-use markets — the health and wellness market now represents a third pillar in the global cannabis industry. The global health and wellness market reached a reported $ 3.7 trillion in 2016 and is expected to grow by 17 percent over the next five years, and cannabis infused products have the potential to play a significant role in that growth.

Whether medical, recreational or health and wellness, the overall cannabis industry is being shaped in large part by downstream cannabis product developers and consumers looking for new ways to integrate the plant’s many benefits into an active and healthy lifestyle. Cannabis product companies are already leveraging consumer desire for more health-conscious and discrete methods of cannabis consumption by offering an increasingly diverse range of cannabis infused products, including cosmetics, sports-recovery shakes, pet care, pain-relieving patches, sleep-inducing sublingual sprays, THC-loaded gummies, anxiety-relieving CBD oils, sex-enhancing topical creams, cereals and meal-replacement bars, and CBD-infused ice teas.

With the emergence of the legal adult-use market, analysts expect cannabis product innovation to continue on an even larger scale. In the North American cannabis retail market alone, sales of cannabis-based products are forecast to increase to $ 20.2 billion in 2021 from $ 6.7 billion last year, according to Arcview Market Research.

Beneficial strategic partnerships in the cannabis market

Cannabis product companies that can supply the medical, recreational and health and wellness markets early on will be strategically positioned as key players in the evolving global cannabis market. As the companies look to better position themselves to take advantage of this opportunity, strategic partnerships in the cannabis market are becoming increasingly popular, and they have many benefits for both partners.

By entering into strategic alliances with licensed producers, downstream cannabis product companies can obtain access to licenses, an established distribution network, as well as the expertise and knowledge of the management team. In over-supplied markets, licensed producers can ensure their flower will not be rotting away waiting for a buyer, but rather go into high margin cannabis consumer products. Brands with marketable cannabis products can partner with licensed producers as a way to enter a new market, either in North America or internationally, which can give both players a lucrative advantage over competitors. These partnerships can provide access to intellectual property and market share, as well as opportunities for further expansion. And product diversification can enhance competitiveness, profitability and brand recognition.

Companies producing downstream cannabis products can vertically-integrate their operations by partnering with a licensed producer on site, cutting costs and controlling product quality. Pharmaceutical company Canntab Therapeutics (CSE:PILL) has a collaborative partnership in place with licensed producer FSD Pharma Inc. (CSE:HUGE). FSD Pharma is providing Canntab with 10,000 square feet of space in its Cobourg facility in return for profit-sharing and the development of a line of cannabis oral dose delivery platforms and other types of cannabis-based products, such as sleep aids and pain relievers. Canntab’s co-location agreement with FSD Pharma also gives them access to the expertise of the World Class Extractions team also onsite as well as their extract products for use in Canntab’s manufacturing process.

“Co-locating with FSD Pharma allows us to differ capital costs but also reduces the footprint of our processes. You can imagine the headache of trying to move large amounts of cannabis material between two locations. Everything under one roof. Costs are minimized as we share space and processes are streamlined as we reduce transportation distances to 0. Having an unbroken chain also helps us satisfy the pharmaceutical standards we must respect,” Canntab CEO Jeff Renwick told Investing News Network. “Once we have the products we can then turn to FSD Pharma to complete the sales, at least until we have our own license application approved which could be as early as mid 2019.”

Canntab has also partnered with another Canadian licensed producer, Emblem Corp (TSXV:EMC,OTCQX:EMMBF), giving Emblem the exclusive right to utilize Canntab’s Extended Release (XR) cannabis tablets in Canada. These proprietary time-released tablets are designed to release a predetermined and consistent dose of cannabinoids over an extended period of time, giving the consumer longer lasting relief while reducing the worry of side effects.

Phivida Holdings Inc (CSE:VIDA,OTCQX:PHVAF) is partnered with WeedMD Inc. (TSXV:WMD,OTCMKTS:WDDMF, FSE:4WE) to develop and operate Cannabis Beverages Inc. (CanBev) at WeedMD’s greenhouse facility in Strathroy, Ontario. The agreement includes product development, manufacturing, marketing and distribution of cannabis-infused beverages for Canada and export to licensed international markets. “The Phivida team is excited to contribute our management, expertise and product knowledge to the CanBev joint venture,” said Jim Bailey, CEO and President of Phivida. “WeedMD is an ideal partner for Phivida and we are thrilled to bring our cannabinoid-infused beverages and brands back home to Canada. WeedMD provides CanBev with solid infrastructure, strong management, world-class genetics and proven success in the Canadian healthcare market.”

These strategic partnerships in the cannabis market can also help companies establish a presence in growing global markets. An established player in the US, Nutritional High (CSE:EAT,OTCQB:SPLIF,FWB:2NU) was able to enter the Canadian market via a strategic partnership with licensed producer Canada House (CSE:CHV). Through Canada House, Nutritional High is able to sell it’s FLÏ brand, gaining a foothold in the Canadian market.

MYM Nutraceutical’s (CSE:MYM) deal with Amsterdam-based Dutch Passion Seed Company is a another good example of strategic partnership with an international edge. MYM has inked a series of production and distribution deals for Dutch Passion branded products and seed genetics in Canada, Australia and Colombia — benefiting the global expansion goals of both companies. “As legal production of cannabis has been rapidly increasing worldwide, so has the demand for seed genetics,” said Rob Gietl, CEO of MYM. “The Dutch Passion portfolio of seeds will prove to be a very valuable asset to MYM and its shareholders.”

Takeaway

As global demand for cannabis products continues to grow, more companies are pursuing strategic partnerships in the cannabis market which will allow their brands to establish a foothold in fast-growing markets. These relationships have significant benefits for both partners as well as providing their investors with better leverage to a global cannabis market with the potential to reach nearly $ 194 billion by 2025.

This INNspired article is sponsored by Canntab Therapeutics (CSE:PILL). This article was written according to INN editorial standards to educate investors. 

The post Better Together: Strategic Partnerships in the Cannabis Market appeared first on Investing News Network.

Investing News Network

Stock Markets Around the World are Crashing. What Not to Worry About?

Article posted at The Market Oracle http://www.marketoracle.co.uk/Article63508.html
The Market Oracle – Financial Markets Analysis and Forecasts – CLICK TO READ ARTICLE

Checkpoint Inhibitors Driving the Immunotherapy Market

Advances in immune checkpoint inhibitor based treatments are shifting the treatment paradigm and could possibly push immunotherapy market sales into $ 100 billion territory by 2022.

The global prevalence of cancer is on the rise, according to a World Health Organization study, with 18 million new cancer cases expected for 2018 alone. More than half of those patients will succumb to their illness. In the United States, the American Cancer Society statistics show that one in three people will be diagnosed with cancer in their lifetime, with the most common diseases being prostate, lung and colorectal for men and breast, lung and colorectal for women.

In fact, breast cancer accounts for 30 percent of all new cancer diagnoses for women. Traditionally, cancer has been treated with chemotherapy, which does have good response rates, but is generally not well-tolerated by patients and recurrences are common. The cancer treatments on the cutting edge of this battle today are primarily immunotherapies, which use the body’s immune system to destroy cancer cells.

This INNspired Article is brought to you by:

BriaCell Therapeutics Corp. (TSX:BCT, OTCQB:BCTXF) is biotechnology company with a mission to develop innovative immunotherapies for treating cancer.Send me an Investor Kit

Breakthroughs in immunotherapy-based cancer research

Developments in immunotherapy research over the past few decades have led to breakthroughs in treatment options and positive outcomes for cancer patients. The most promising class of cancer-fighting drugs are the immune checkpoint inhibitors that target the proteins found on T-lymphocytes or T cells such as programmed cell death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) and proteins found on the cancer such as programmed death ligand 1 (PD-L1).

“Immunotherapy takes advantage of the patient’s own immune system to combat cancer. The currently approved immunotherapies work by blocking immune checkpoints. These checkpoints are like off switches for the immune response. This approach is tolerated much better than traditional chemotherapies,” Dr. William V. Williams, former VP of Exploratory Development at Incyte Corporation, former VP of Clinical Pharmacology at GlaxoSmithKline and current President and CEO of BriaCell Therapeutics Corp. (TSXV:BCT,OTCQB:BCTXF), told Investing News Network.

These immune checkpoints were first identified by the 2018 Nobel prize-winning work of American James Allison and Tasuku Honjo from Japan. Through their separate decades-long research, both Dr. Allison and Dr. Honjo developed ways to weaponize and recruit the immune system in the fight against cancer by putting the brakes on immune checkpoint proteins, unleashing the immune system’s powerful T-cell response mechanisms to attack cancer cells. The result has been much improved patient outcomes including lower incidence of side effects compared to chemotherapy and less chance of recurrence.

In 2011, Dr. Allison’s research helped bring ipilimumab (Bristol-Myers Squibb’s anti-CTLA-4 therapy Yervoy®), the first FDA-approved immune checkpoint inhibitor, to market for the treatment of advanced melanoma. Dr. Honjo’s research led to the development of pembrolizumab (Merck & Co’s PD-1 therapy Keytruda®) and nivolumab (Bristol-Myers Squibb’s PD-L1 therapy Opdivo®,), both of which were approved by the FDA in 2014 for the treatment of advanced melanoma. Their discoveries have led to a multibillion-dollar market for new cancer medicines.

“Cancer kills millions of people every year and is one of humanity’s greatest health challenges,” said the Nobel committee. “By stimulating the inherent ability of our immune system to attack tumor cells, this year’s Nobel Laureates have established an entirely new principle for cancer therapy.”

About 20 percent of patients who underwent treatment with immune checkpoint inhibitors during Allison and Honjo’s clinical studies survived at least 3 years posttreatment, and many have lived for 10 years and beyond, including one metastatic melanoma patient who is still alive nearly 19 years later following one dose of ipilimumab.

Today, immunotherapy ranks alongside the more traditional approaches of radiation, surgery and chemotherapy in the fight against cancer, greatly expanding the treatment options available to patients.

“We’ve gone from being in a situation where patients were effectively untreatable to having a range of immunotherapy options that, when they work, work very well indeed,” said Kevin Harrington, a professor at the Institute of Cancer Research in London. “For some patients we see their tumors shrink or completely disappear and are effectively cured.”

Cancer immunotherapy market size

The global immunotherapy market totaled nearly US$ 30 billion in 2017 and is expected to reach $ 100 billion by 2022, propelled by increasing global cancer rates, rising healthcare expenditures and the emergence of novel agents to the market.

Immune checkpoint inhibitors are one of the largest and highest growth segments in this space owing to their low cost, greater efficiency and overall success rates compared to traditional first-line treatments. The North American regional market is expected to account for the largest share of this growth, fueled by government initiatives for further development of advanced cancer treatments.

In addition to Keytruda®, Opdivo® and Yervoy®, three other checkpoint inhibitors have received FDA approval for the treatment of cancer, including Tecentriq (atezoliumab), Bavencio (avelumab) and Imfinzi (durvalumab), all of which target PD-L1.

The primary cancer immunotherapy market players are Bristol-Myers Squibb, Merck, Novartis, AstraZeneca, Pfizer, Genentech/Roche, Jansen, Eli Lilly, Incyte, Celgene, Amgen and a number of smaller companies such as Juno, Kite, Immunovaccine and BriaCell.

Immune checkpoint inhibitor combination therapies

Advancement in novel delivery technologies (including monoclonal antibodies and small molecule drugs) and combination therapies are where the real growth will be in the immunotherapy market. “What we’re looking forward to is combinations, not just of multiple checkpoints but of checkpoints with radiation, checkpoints with chemotherapy, [and] checkpoints with genetically targeted small molecule drugs,” Dr. Allison said in a press conference. “Immunotherapy is going to be part, it’s not going to replace the others, but it’s going to be part of the therapy that essentially all cancer patients are going to be receiving in 5 years.”

Clinical trials are now underway evaluating the effectiveness of immune checkpoint inhibitor therapies in combination with chemotherapy or other targeted therapies across a variety of cancer subtypes, including kidney, lung, ovarian and breast cancer.

Bristol-Myers Squibb (NYSE:BMY) and Compugen (NASDAQ:CGEN) are collaborating in clinical trials to evaluate the safety and tolerability of the Israel-based company’s investigational antibody COM701 in combination with the pharma giant’s immune checkpoint inhibitor Opdivo®. These early stage trials will target patients suffering from non-small cell lung, ovarian, breast and endometrial cancer, with advanced solid tumors.

Along with the clinical study collaboration, Bristol-Myers Squibb will invest $ 12 million in Compugen. “From a business perspective, these collaborations have tremendous impact on small companies working with larger pharmaceutical companies. Innovation often begins in small companies. Larger companies become interested and either license the technology or collaborate with the smaller company,” explained Dr. Williams, who has been a biopharmaceutical executive and clinical professional for nearly four decades. “These collaborations can take several forms, but they help validate the technology being developed by the smaller company. This can boost their credibility and also lead to a longer-term business relationship with the larger company.”

Merck’s (NYSE:MRK) pivotal Phase 3 KEYNOTE-426 trial investigating Keytruda® — the leading immunotherapy for treating lung cancer — in combination with Pfizer’s (NYSE:PFE) tyrosine kinase inhibitor Inlyta®(axitinib) has shown a significant benefit on both overall and progression-free survival as a first-line treatment for advanced or metastatic renal cell carcinoma, the most common form of kidney cancer.

“This marks the first time that combination treatment with an anti-PD-1 therapy has achieved the dual primary endpoints of overall survival and progression-free survival as first-line therapy in advanced renal cell carcinoma,” said Dr. Roger M. Perlmutter, President, Merck Research Laboratories. “Fewer than 10 percent of those diagnosed with advanced renal cell carcinoma survive for five years, and hence there is significant need for improved therapies for this disease.” The results will be submitted to regulatory authorities worldwide.

BriaCell recently announced that based on its positive proof of concept data from its Phase 2a clinical study of Bria-IMT™ in advanced breast cancer patients, the company will now initiate a study focusing on the combination of Bria-IMT™ with Merk’s Keytruda®. BriaCell’s lead clinical candidate, Bria-IMT™ is genetically engineered to secrete an immune system activator, GMCSF, which activates antigen presenting cells that then mobilize the T-cells in a patient’s immune system to recognize cancer cells and eliminate them. Dr. Williams believes that Bria-IMT™ is also directly recognizable to the immune system’s T-cells, acting as an antigen presenting cell and boosting the immune response against the cancer cells — a key effect which may set Bria-IMT™ apart from other similar targeted immunotherapies.

“This top-line data compares very well with data from existing breast cancer therapies which have a sizable market share when they were at a similar stage of clinical development, as well as with other promising breast cancer treatments currently under study,” said Dr. Williams. “In our view, the combination of Bria-IMT™ with Keytruda® has the potential to provide a new therapeutic option and substantial clinical benefit in heavily pre-treated advanced breast cancer patients where there remains a significant unmet need.”

Looking forward

Cancer in all its vulgar varieties threatens and takes the lives of millions of men and women around the globe each year. Nobel Prize-winning Doctors Allison and Honjo set modern medicine on the right path, but today’s Pharmaceutical companies focused on paradigm shifting advancements in first-line cancer treatments are bringing humanity even closer to stamping out this cruel disease.

This INNspired article is sponsored by BriaCell Therapeutics (TSX:BCT,OTCQB:BCTXF). This article was written according to INN editorial standards to educate investors. 

The post Checkpoint Inhibitors Driving the Immunotherapy Market appeared first on Investing News Network.

Investing News Network

FR. 1994-L 2009 $5 FEDERAL RESERVE NOTE SAN FRANCSICO – PMG GEM UNC-66EPQ

$19.95 (0 Bids)
End Date: Sunday Nov-18-2018 17:30:08 PST
Bid now | Add to watch list

View full post on

2017-W Silver Eagle-PCGS MS-70 (First Strike)

$0.99 (0 Bids)
End Date: Thursday Nov-22-2018 15:38:55 PST
Bid now | Add to watch list

View full post on

Stock Trade-of-the-Week: Equity Commonwealth REIT (EQC)

Article posted at The Market Oracle http://www.marketoracle.co.uk/Article63509.html
The Market Oracle – Financial Markets Analysis and Forecasts – CLICK TO READ ARTICLE

High Hampton Closes Acquisition of Mojave Jane, Licensed California Cannabis Manufacturing Company

High Hampton Holdings Corp (CSE:HC,OTCMKTS:HHPHF FSE:OHCN) (“High Hampton” or the “Company”) is pleased to report that it has successfully closed the previously announced transaction to acquire 100% of all of the issued and outstanding member interests in Mojave Jane, LLC (“Mojave Jane”)  (the “Acquisition”). The Acquisition adds a fifth 100%-owned subsidiary to High Hampton’s growing portfolio of California-based cannabis manufacturers and distributors, and, in addition to profits already generating from its other brands, is also expected to add near-term revenue to the Company’s bottom line.

Mojave Jane, LLC is a California licensed manufacturer of premium cannabis extracts and concentrates for the Californiamarkets.  Based in Coachella, CA, and licensed for both volatile and non-volatile manufacturing, Mojave Jane currently utilizes state of the art CO2 extraction technologies and proven distillation techniques to create products for both recreational and medical cannabis users.  Mojave Jane’s management team includes an accomplished group of business executives with experience in starting, growing, and selling companies, combined with hands-on commercial cannabis experience.  Mojave Jane is a key part of the Coachella Valley’s growing cannabis economy and supports distribution throughout California.

Under the terms of the Acquisition, all of Mojave Jane’s issued and outstanding member interests were exchanged for 8,974,352 common shares of High Hampton (the “Share Exchange”) with the shares being subject to escrow until certain milestone conditions are met, triggering a staggered share release. High Hampton will also commit up to US$ 1,100,000to Mojave Jane for expansion of its manufacturing capacity, marketing, sales and working capital.

Christian Scovenna, Interim CEO & Director of High Hampton, commented:

“As the High Hampton family of subsidiaries grows, we are continuously strengthening our position as a strong player in the burgeoning California cannabis market. Adding Mojave Jane to our portfolio means bringing on more market expertise, cannabis products and revenue and will help us grow our share in the adult use market. We will continue to act as a key consolidator in this space adding shareholder value through both internal and external growth.”

Gary Latham, a founding partner of Mojave Jane, added:

“The Partners at Mojave Jane have worked together to build a world-class manufacturing facility in Coachella to produce the kind of high quality distillate the market demands. We have succeeded at making that happen, and at navigating the complex California regulatory environment to become a viable part of California’s growing cannabis economy.

Now we are ready to scale and produce quality products that meet the needs of medical and adult use markets as they take root in the legal cannabis ecosystem. High Hampton provides us with the means to scale and to more fully integrate our production capacity with High Hampton’s other subsidiaries in California. In turn, Mojave Jane will deliver value to High Hampton’s shareholders through near term revenue and an increased branding footprint. It’s a great time to be a part of this growth with High Hampton and throughout California.”

About High Hampton Holdings Corp.

High Hampton Holdings Corp. is a cannabis sector investment company focused on opportunities in California striving to become the largest consolidator in the medicinal cannabis sector. The Company has assembled a stellar team with cannabis, capital markets, compliance, political, licensing and brands & products supply chain experience and aggressively develops its wholly owned subsidiaries toward sustainable growth and active operations:

CoachellaGro Corp., a California corporation focused on the development of a 254,000 sq ft. greenhouse facility situated in the cannabis industrial park located in Coachella, California with a valid conditional use permit (CUP) for the development of a full-service production facility in order to serve third party state licensed medicinal marijuana operators.

420 Realty, LLC has applied for multiple permits to vertically integrate in the City of Cudahy, CA (Greater Los Angeles Area), for a development agreement (DA) including cannabis cultivation, nursery, manufacturing, delivery, and distribution licenses on a single parcel location. 8 Points Management, LLC serves the cannabis industry with sales, marketing, transportation, and supply chain management services through its subsidiary Bravo Distro LLC. Bravo’s customers include California storefront dispensaries, delivery services, and chain stores, as well as non-retail accounts of cannabis such as manufacturers, cultivators, and the emerging CBD medical market of clinics, universities, research, veterinary, and other sciences with an expanding customer base.

CALIGOLD is serving the edibles market by crafting America’s finest quality “medicinal-grade” cannabis edible products combining art and science to deliver innovative creations and adhere to important industry standards in consistency, dosing accuracy, and compound formulation.

Mojave Jane, LLC is a California licensed manufacturer of premium cannabis extracts and concentrates for the California markets.  Based in Coachella, CA, and licensed for both volatile and non-volatile manufacturing, Mojave Jane currently utilizes state of the art CO2 extraction technologies and proven distillation techniques to create products for both recreational and medical cannabis users.

Social Media

Facebook: facebook.com/highhampton
Twitter: twitter.com/highhamptonHC
LinkedIn: linkedin.com/HighHampton

Stock Exchanges

High Hampton trades in Canada, ticker symbol HC on the CSE, and in Europe, ticker symbol 0HCN on the FSE. Neither the CSE, nor the FSE has approved nor disapproved the contents of this press release. Neither the CSE, nor the FSE accepts responsibility for the adequacy or accuracy of this release.

Marijuana Industry Involvement

Canadian listings (CSE) will remain in good standing as long as they provide the disclosure that is rightly required by regulators and complying with applicable licensing requirements and the regulatory framework enacted by the applicable state in which they operate. Marijuana is legal in certain states however marijuana remains illegal under US federal law and the approach to enforcement of US federal law against marijuana is subject to change. Shareholders and investors need to be aware that adverse enforcement actions could affect their investments and that High Hampton’s ability to access private and public capital could be affected and or could not be available to support continuing operations.

On behalf of the Board of Directors

High Hampton Holdings Corp.

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the intention of the parties to complete the Acquisition and certain ancillary transactions contemplated thereby. These transactions are subject to a number of material risks, and there is no assurance that they will be completed on the terms or within the timeframes currently contemplated, or at all. The forward-looking information contained in this press release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

All monetary references herein refer to Canadian dollars unless otherwise specified.

None of the securities issued pursuant to the Acquisition have been or will be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and any securities issued pursuant to the Acquisition were issued in reliance upon available exemptions from such registration requirements pursuant to Rule 506(b) of Regulation D and/or Section 4(a)(2) of the U.S. Securities Act and applicable exemptions under state securities laws. In addition, the securities issued under an exemption from the registration requirements of the U.S. Securities Act are “restricted securities” as defined under Rule 144(a)(3) of the U.S. Securities Act and contain the appropriate restrictive legend as required under the U.S. Securities Act.

Click here to connect with High Hampton Holdings Corp (CSE:HC,OTCMKTS:HHPHF FSE:OHCN) for an Investor Presentation.

The post High Hampton Closes Acquisition of Mojave Jane, Licensed California Cannabis Manufacturing Company appeared first on Investing News Network.

Investing News Network

1995 $2 FRN Note FR# 1936-F (FB Block) Withrow / Rubin PMG 66 EPQ Gem Unc.

$59.95
End Date: Saturday Dec-1-2018 15:10:09 PST
Buy It Now for only: $59.95
Buy It Now | Add to watch list

View full post on

2016 $1 Silver Eagle MS70 PCGS 30th Anniversary John Mercanti ASE label SPOTTED

$49.00
End Date: Wednesday Dec-12-2018 11:08:39 PST
Buy It Now for only: $49.00
Buy It Now | Add to watch list

View full post on

Netflix (NFLX): When Bulls and Bears Collide

Article posted at The Market Oracle http://www.marketoracle.co.uk/Article63507.html
The Market Oracle – Financial Markets Analysis and Forecasts – CLICK TO READ ARTICLE

MediPharm Labs Corp. Receives Sales Licence from Health Canada

MediPharm Labs Corp. (TSXV:LABS) (“MediPharm Labs” or the “Company”) is pleased to announce that its wholly-owned subsidiary, MediPharm Labs Inc., has received its sales licence from Health Canada (the “Sales Licence”) pursuant to the Cannabis Act. The Sales Licence relates to the Company’s wholly-owned laboratory and manufacturing facilities in Barrie, Ontario.

“This Sales Licence represents a significant milestone for MediPharm Labs and a key component of our strategy to be a producer of cannabis concentrates at a globally-recognized quality standard, while also being focused on revenues, profitability and value to our shareholders, partners and constituents,” says Pat McCutcheon, co-founder and CEO of MediPharm Labs.

A first-mover in cannabis extraction and purification in Canada, MediPharm Labs has invested in an expert team, customized state-of-the-art technology, proprietary methodologies and purpose-built facilities to deliver pharmaceutical-grade and precisely dosable cannabis oils and cannabis concentrates for advanced derivative products. Purified cannabis concentrates have emerged as a preferred basis for consumption and are also the critical elements for isolates and infused products for both the medical and adult use markets where legal globally. MediPharm Labs has been actively building an inventory of specialized cannabis concentrates and isolates in anticipation of receiving its licence, to serve both the medical cannabis and adult-use markets in Canada.

After having obtained its Sales Licence from Health Canada, MediPharm Labs is positioned to fulfill its role in the Canadian cannabis supply chain by delivering advanced oil strategies to its previously announced, innovative and well-established industry partners:

• MediPharm Labs has one of only 32 supply agreements with the Ontario Cannabis Stores

• The Company has signed four multi-year cannabis concentrate program agreements with partner licensed cultivators:

• MediPharm Labs has a 1,200 kg supply agreement with UP Cannabis Inc. (TSXV:HIP) as announced on September 24, 2018

• Through JV “Garden Variety”, the Company expects to supply four future retail stores in Manitoba that have received provincial approval for bricks and mortar stores as announced on August 22, 2018

MediPharm Labs has completed the purification and production of over 180,000 g of cannabis extract.

MediPharm Labs is research-driven and focused on downstream secondary extraction methodology, distillation and cannabinoid isolation and purification. MediPharm Labs currently operates one of the largest cannabis concentrate manufacturing facilities in Canada and is built to cGMP (current Good Manufacturing Practices) and ISO standards. Leveraging MediPharm Lab’s proprietary pharmaceutical manufacturing expertise, the Company currently has Phase 1 capacity to process over 100,000 kg of dry cannabis per year. With Phase 2 funded and expected to be completed by the end of Q2 2019, the Company anticipates that its processing capacity will more than double to up to 250,000 kg annually upon the completion of such expansion.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/d4559661-f73d-4ed5-84d8-1ad3f4502eaf

About MediPharm Labs Corp.

MediPharm Labs, through its subsidiary, is a pioneer in the cannabis industry and has the distinction of being the first company in Canada to become a licensed producer for cannabis oil production under the Access to Cannabis for Medical Purposes Regulations (ACMPR)without first receiving a cannabis cultivation licence. This expert focus on cannabis concentrates from our cGMP (current Good Manufacturing Practices) and ISO standard clean rooms and critical environments laboratory, allows MediPharm Labs to work with its established, Health Canada-approved cultivation partners to produce pharmaceutical-grade cannabis oil with a competitive advantage. MediPharm Labs is research-driven and focused on downstream secondary extraction methodology, distillation, and cannabinoid isolation and purification. MediPharm Labs, through its subsidiary, provides B2B contract processing of cannabis to Canadian authorized licensed producers and appropriate international growers, supplying integrity-assured cannabis oil to qualified companies for sale under their own brand.

MediPharm Labs will supply raw materials, formulations, processing and packaging for the creation of ready-to-sell advanced derivative products. Through its subsidiary, MediPharm Labs Australia Pty. Ltd., MediPharm Labs has also completed its application process with the federal Office of Drug Control to extract and import medical cannabis products in Australia.

Further Information

For additional information, please see the Company’s website at www.medipharmlabs.com or contact:

Pat McCutcheon, CEO and President of MediPharm Labs
Phone:             705-719-7425 ext. 216
Email:              investors@medipharmlabs.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, the Company’s joint venture in Manitoba, the expected completion date of the Company’s expansion, anticipated processing capacities, and operations in Australia. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; and the delay or failure to receive regulatory approvals. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, the Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.

Click here to connect with MediPharm Labs Corp. (TSXV:LABS) for an Investor Presentation.

The post MediPharm Labs Corp. Receives Sales Licence from Health Canada appeared first on Investing News Network.

Investing News Network

AC 1969 $100 Chicago *star* FRN PMG 66 EPQ G-* block Fr 2164-G*

$499.00
End Date: Wednesday Dec-12-2018 5:07:35 PST
Buy It Now for only: $499.00
Buy It Now | Add to watch list

View full post on

2012-(W) $1 American Silver Eagle 1 Oz .999 Silver – PCGS MS 70 – First Strike

$33.00 (8 Bids)
End Date: Monday Nov-12-2018 14:59:35 PST
Bid now | Add to watch list

View full post on

One Direction More Likely for Bitcoin Price

Article posted at The Market Oracle http://www.marketoracle.co.uk/Article63500.html
The Market Oracle – Financial Markets Analysis and Forecasts – CLICK TO READ ARTICLE

Spanish treasure propels Sedwick sale results

What do you imagine when you think about treasure recovered from sunken Spanish galleons?

Silver bars?

Pieces of eight?

Many coin collectors dream of these.

Imagine making them the basis of your business.

That is what the Florida firm of Daniel Frank Sedwick LLC does.

Results of its Nov. 2-3 public sale and Nov. 5 online sale have just reached my desk courtesy of Connor Falk.

The sale featured 2,300 lots.

It realized over $ 3.1 million, including a 19 percent buyer’s fee.

This is a record for the firm, Falk said.

In other words, the treasure business is booming.

Let’s start with the silver bars.

Falk pinpointed two.

“Strong bids were placed for two large silver bars, lots 256 and 257, recovered from the shipwreck of the Atocha, sunk in 1622 off Key West, Fla.

“Both bars came with Mel Fisher photo-certificates, were graded Class Factor 1.0, were of similar weight (83 troy pounds, 2.3 troy ounces and 81 troy pounds, 6.56 troy ounces, respectively), and estimated at $ 30,000 to $ 45,000 each.

“The bars ended up selling for $ 59,500 and $ 56,525, respectively.”

A troy pound contains 12 troy ounces, so the first bar weighed 998.3 ounces.

Sale price works out to $ 59.60 an ounce, which is far higher than a modern ounce sells for, which traded at $ 14.03 this morning as reported by www.Kitco.com.

The second bar is 978.56 ounces.

This works out to $ 57.76 an ounce.

Bars and coins from the Spanish Empire in the New World were shipped to Imperial Spain.

An early coin from Mexico City sold for $ 83,300 on an estimate of $ 35,000-$ 70,000.

This was a Charles and Joanna “Early Series” 3 reales graded Numismatic Guaranty Corporation VF30 in lot 664.

Charles was the reigning king of Spain when Cortes took over the Aztec Empire beginning in 1519.

The coin is from about two decades later.

The Sedwick auction also featured world coin rarities led by a six-coin set of gold pieces from Cuba dated 1915.

Each coin in the set was sold individually, but they were all purchased by the same buyer.

The total of the six prices realized was $ 473,025.

Falk noted that the “1, 2, 4, 10 and 20 pesos are specimen strikes and certified as such by NGC.

“They are the only known specimen strikes for the series.

“The sixth coin, a 5 pesos, was graded NGC MS 66+ for its exceptional surfaces and is the finest graded for the type.”

That’s quite a set.

It must be fascinating to be able to handle such rarities instead of just writing about them.

That’s the trade-off Falk made.

I am proud to say that he once worked in the Numismatic News office, where his career was launched.

Working on sales like this is a great demonstration of success.

Congratulations to the Sedwick firm and to Connor Falk.

I look forward to reports of many more sales to come in the future.

See the full results on the Sedgwick website.

Buzz blogger Dave Harper won the Numismatic Literary Guild Award for Best Blog for the third time in 2017. He is editor of the weekly newspaper “Numismatic News.”

 

The post Spanish treasure propels Sedwick sale results appeared first on Numismatic News.

Buzz – Numismatic News

How “Free Money” Helped Create Sizzling Housing Market & REIT Gains

Article posted at The Market Oracle http://www.marketoracle.co.uk/Article63501.html
The Market Oracle – Financial Markets Analysis and Forecasts – CLICK TO READ ARTICLE